These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 11236335)

  • 1. [Depressive disorders in neurologic rehabilitation: therapy with paroxetine].
    Erfurth A; Loew M; Wendler G; Floreanu A
    Psychiatr Prax; 2001 Jan; 28(1):43-4. PubMed ID: 11236335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin syndrome produced by paroxetine and low-dose trazodone.
    Reeves RR; Bullen JA
    Psychosomatics; 1995; 36(2):159-60. PubMed ID: 7724720
    [No Abstract]   [Full Text] [Related]  

  • 3. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
    Boulenger JP; Hermes A; Huusom AK; Weiller E
    Curr Med Res Opin; 2010 Mar; 26(3):605-14. PubMed ID: 20067433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients.
    Stuppaeck CH; Geretsegger C; Whitworth AB; Schubert H; Platz T; König P; Hinterhuber H; Fleischhacker WW
    J Clin Psychopharmacol; 1994 Aug; 14(4):241-6. PubMed ID: 7962679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxetine versus placebo: a double-blind comparison in depressed patients.
    Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC
    J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
    Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia.
    Pae CU; Masand PS; Marks DM; Krulewicz S; Peindl K; Mannelli P; Patkar AA
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(6):996-1002. PubMed ID: 19433129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine and akathisia.
    Adler LA; Angrist BM
    Biol Psychiatry; 1995 Mar; 37(5):336-7. PubMed ID: 7748986
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid cycling triggered by pindolol augmentation of paroxetine, but not with desipramine.
    Kraus RP
    Depression; 1996; 4(2):92-4. PubMed ID: 9160648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of mania in depression by paroxetine.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Oct; 18(7):565-8. PubMed ID: 14533140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemistry and paroxetine response in major depression.
    Goodnick PJ; Henry J; Kumar A
    Biol Psychiatry; 1995 Mar; 37(6):417-9. PubMed ID: 7772652
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.
    Gibiino S; Mori E; De Ronchi D; Serretti A
    J Clin Psychopharmacol; 2013 Aug; 33(4):565-9. PubMed ID: 23764690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Paroxetine augmentation with risperidone in therapy-resistant depression].
    Knopf U; Hubrich-Ungureanu P; Thome J
    Psychiatr Prax; 2001 Nov; 28(8):405-6. PubMed ID: 11721229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period.
    Kreider MS; Bushnell WD; Oakes R; Wheadon DE
    J Clin Psychiatry; 1995 Apr; 56(4):142-5. PubMed ID: 7713852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.